Targeting mTOR signaling for lung cancer therapy.
Sun
Shi-Yong
SY
Departments of Hematology & Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA. shi-yong.sun@emoryhealthcare.org
Fu
Haian
H
Khuri
Fadlo R
FR
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects; D004273:DNA, Neoplasm / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009154:Mutation; D019869:Phosphatidylinositol 3-Kinases; D011494:Protein Kinases / Q000235:genetics* / Q000378:metabolism; D020123:Sirolimus / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D004273:DNA, Neoplasm; D019869:Phosphatidylinositol 3-Kinases; D011494:Protein Kinases; D020123:Sirolimus; D058570:TOR Serine-Threonine Kinases; C546842:MTOR protein, human